A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned

The global SARS-CoV-2 pandemic prompted rapid development of COVID-19 vaccines. Although several vaccines have received emergency approval through various public health agencies, the SARS-CoV-2 pandemic continues. Emergent variants of concern, waning immunity in the vaccinated, evidence that vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Connor, Megan A., Hawman, David W., Meade-White, Kimberly, Leventhal, Shanna, Song, Wenjun, Randall, Samantha, Archer, Jacob, Lewis, Thomas B., Brown, Brieann, Fredericks, Megan N., Sprouse, Kaitlin R., Tunggal, Hillary C., Maughan, Mara, Iwayama, Naoto, Ahrens, Chul, Garrison, William, Wangari, Solomon, Guerriero, Kathryn A., Hanley, Patrick, Lovaglio, Jamie, Saturday, Greg, Veesler, David, Edlefsen, Paul T., Khandhar, Amit P., Feldmann, Heinz, Fuller, Deborah Heydenburg, Erasmus, Jesse H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150980/
https://www.ncbi.nlm.nih.gov/pubmed/37075079
http://dx.doi.org/10.1371/journal.ppat.1011298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150980/
https://www.ncbi.nlm.nih.gov/pubmed/37075079
http://dx.doi.org/10.1371/journal.ppat.1011298

Ejemplares similares